Impact of Repeated Variant Exposures on Cellular and Humoral Immunogenicity Induced by SARS-CoV-2 Vaccines

被引:0
|
作者
Fernandez-Ciriza, Leire [1 ]
del Pozo, Jose Luis [1 ,2 ,3 ]
Betanzos, Nazaret [1 ]
Gonzalez, Alvaro [2 ,4 ]
Fernandez-Montero, Alejandro [2 ,5 ]
Carmona-Torre, Francisco [2 ,3 ]
Vidaurreta, Marta [1 ,2 ,4 ]
Carlos, Silvia [2 ,6 ]
Reina, Gabriel [1 ,2 ]
机构
[1] Clin Univ Navarra, Dept Microbiol, Pamplona 31008, Spain
[2] Navarra Inst Hlth Res IdiSNA, Pamplona 31008, Spain
[3] Clin Univ Navarra, Infect Dis Div, Pamplona 31008, Spain
[4] Clin Univ Navarra, Dept Biochem, Pamplona 31008, Spain
[5] Univ Navarra, Dept Occupat Med, Pamplona 31008, Spain
[6] Univ Navarra, Dept Prevent Med & Publ Hlth, Pamplona 31008, Spain
关键词
mRNA vaccine; Omicron; reinfection; cellular immunity; humoral immunity; fourth dose; COVID-19;
D O I
10.3390/vaccines12121408
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background/Objectives: The emergence of the Omicron variant has complicated COVID-19 control and prompted vaccine updates. Recent studies have shown that a fourth dose significantly protects against infection and severe disease, though long-term immunity data remain limited. This study aimed to assess Anti-S-RBD antibodies and interferon-gamma levels in healthcare workers 12 months after receiving bivalent Original/Omicron BA.4-5 fourth SARS-CoV-2 vaccine. Methods: In this prospective cohort study, 549 healthcare workers were categorized by the initial vaccination schedule, with 229 individuals having received the fourth SARS-CoV-2 vaccine dose. Blood samples were collected from all participants 12 months post-vaccination. Results: Significant differences in Anti-S-RBD antibody levels were observed between those receiving a fourth dose and those who did not, while no differences were seen in interferon-gamma levels. After 12 months, there were no significant differences in humoral and cellular immunity response between volunteers primoinfected or reinfected across different periods by the Omicron variant. A multivariable analysis revealed an association between high antibody levels (>6000 U/mL) and interferon-gamma levels (OR: 3.13; 95% CI: 1.3-7.7; p < 0.05). Regarding primary vaccine schedules, participants vaccinated with ChAdOx1 (a single or double dose) had notably lower antibody levels compared to those who received mRNA-based vaccines. Additionally, the study shows a higher frequency of multiple infections among those with a single-dose ChAdOx1 primary schedule (OR: 6.24; 95% CI: 1.25-31.15; p < 0.01). Conclusions: Overall, mRNA-based vaccines exhibited stronger long-term immunogenicity. Repeated exposure to the Omicron variant seems to mitigate immune imprinting from the wild-type SARS-CoV-2. An association was observed between high antibody levels and a strong cellular response, although the correlation was not linear.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] The Impact of Immunosuppression on the Humoral Immunogenicity of SARS-CoV-2 mRNA Vaccines in SLE
    Sadun, Rebecca
    Crair, Dan
    Walter, Emmanuel B.
    Rogers, Jennifer
    Clowse, Megan
    Eudy, Amanda
    Sun, Kai
    Doss, Jayanth
    Criscione-Schreiber, Lisa
    Valencia, Sarah
    Moody, M. Anthony
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 408 - 410
  • [2] HUMORAL AND CELLULAR IMMUNOGENICITY INDUCED BY THIRD BOOSTER OF SARS-COV-2 VACCINES IN PATIENTS WITH RHEUMATIC MUSCULOSKELETAL DISEASES
    Kondo, Y.
    Takeshita, M.
    Saito, S.
    Kikuchi, J.
    Hanaoka, H.
    Suzuki, K.
    Kaneko, Y.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1869 - 1869
  • [3] Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study
    Haydu, J. Erika
    Maron, Jenny S.
    Redd, Robert A.
    Gallagher, Kathleen M. E.
    Fischinger, Stephanie
    Barnes, Jeffrey A.
    Hochberg, Ephraim P.
    Johnson, P. Connor
    Takvorian, R. W.
    Katsis, Katelin
    Portman, Daneal
    Ruiters, Jade
    Sechio, Sidney
    Devlin, Mary
    Regan, Connor
    Blumenthal, Kimberly G.
    Banerji, Aleena
    Judd, Allen D.
    Scorsune, Krista J.
    McGree, Brianne M.
    Sherburne, Maryanne M.
    Lynch, Julia M.
    Weitzman, James I.
    Lei, Matthew
    Kotton, Camille N.
    Dighe, Anand S.
    Maus, Marcela V.
    Alter, Galit
    Abramson, Jeremy S.
    Soumerai, Jacob D.
    BLOOD ADVANCES, 2022, 6 (06) : 1671 - 1683
  • [4] Humoral and cellular immunogenicity two months after SARS-CoV-2 messenger RNA vaccines in patients with cancer
    Bordry, Natacha
    Addeo, Alfredo
    Jaksic, Cyril
    Dutoit, Valerie
    Roux-Lombard, Pascale
    Shah, Dimpy P.
    Shah, Pankil K.
    Gayet-Ageron, Angele
    Friedlaender, Alex
    Bugeia, Sebastien
    Gutknecht, Garance
    Battagin, Anna
    Di Marco, Maragrazia
    Simand, Pierre-Francois
    Ladibi-Galy, Intidhar
    Fertani, Sarah
    Sandoval, Jose
    Dietrich, Pierre-Yves
    Mach, Nicolas
    ISCIENCE, 2022, 25 (01)
  • [5] Immunogenicity of SARS-CoV-2 vaccines in with cancer
    Kakkassery, Helen
    Carpenter, Esme
    Patten, Piers E. M.
    Irshad, Sheeba
    TRENDS IN MOLECULAR MEDICINE, 2022, 28 (12) : 1082 - 1099
  • [6] Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis
    Strengert, Monika
    Becker, Matthias
    Ramos, Gema Morillas
    Dulovic, Alex
    Gruber, Jens
    Juengling, Jennifer
    Luerken, Karsten
    Beigel, Andrea
    Wrenger, Eike
    Lonnemann, Gerhard
    Cossmann, Anne
    Stankov, Metodi, V
    Dopfer-Jablonka, Alexandra
    Kaiser, Philipp D.
    Traenkle, Bjoern
    Rothbauer, Ulrich
    Krause, Gerard
    Schneiderhan-Marra, Nicole
    Behrens, Georg M. N.
    EBIOMEDICINE, 2021, 70
  • [7] Humoral immunogenicity of mRNA SARS-COV-2 vaccines among people living with HIV
    Robles, A. G.
    Nomah, D. K.
    Bruguera, A.
    Tiraboschi, J. M.
    Benet, S.
    Garcia-Perez, J.
    Jimenez, P.
    Sanchez-Palomino, S.
    Suanzes, P.
    Garcia-Gazalla, M.
    Homar, F.
    Mothe, B.
    Reyes-Uruena, J.
    Buzon, M. J.
    Miro, J. M.
    HIV MEDICINE, 2023, 24 : 295 - 296
  • [8] Intranasal SARS-CoV-2 Omicron variant vaccines elicit humoral and cellular mucosal immunity in female mice
    Slamanig, Stefan
    Gonzalez-Dominguez, Irene
    Chang, Lauren A.
    Lemus, Nicholas
    Lai, Tsoi Ying
    Martinez, Jose Luis
    Singh, Gagandeep
    Dolange, Victoria
    Abdeljawad, Adam
    Kowdle, Shreyas
    Noureddine, Moataz
    Warang, Prajakta
    Lee, Benhur
    Garcia-Sastre, Adolfo
    Krammer, Florian
    Schotsaert, Michael
    Palese, Peter
    Sun, Weina
    EBIOMEDICINE, 2024, 105
  • [9] CELLULAR AND HUMORAL IMMUNOGENICITY OF THE NEOANTIGEN S1 FROM SARS-COV-2 VACCINES IN PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASES
    Alvarez Hernandez, M. P.
    Perez-Sancristobal, I.
    Mohamed Mohamed, K.
    Rodriguez Laguna, M.
    Martinez Prada, C.
    Freites, D.
    Toledano Martinez, M. E.
    Fernandez, B.
    Rodero, M.
    Bravo, C.
    Rodriguez de la Pena, A.
    Sanchez-Ramon, S.
    Mato Chain, G.
    Candelas, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 533 - 534
  • [10] Humoral and Cellular Immunogenicity of Six Different Vaccines against SARS-CoV-2 in Adults: A Comparative Study in Tunisia (North Africa)
    Ben Ahmed, Melika
    Bellali, Hedia
    Gdoura, Mariem
    Zamali, Imen
    Kallala, Ouafa
    Ben Hmid, Ahlem
    Hamdi, Walid
    Ayari, Hela
    Fares, Hajer
    Mechri, Karim
    Marzouki, Soumaya
    Triki, Henda
    Ben Alaya, Nissaf
    Chahed, Mohamed Kouni
    Klouz, Anis
    Sebai Ben Amor, Sonia
    Ben Rayana, Chiheb
    Razgallah Khrouf, Myriam
    Hamouda, Chokri
    Elkadri, Noomene
    Daghfous, Riadh
    Trabelsi, Abdelhalim
    VACCINES, 2022, 10 (08)